(Q52011544)

19 April 2018

title

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. (English)

1 reference

19 April 2018

1 reference

Steinberg P

1

1 reference

19 April 2018

McNutt BE

2

1 reference

19 April 2018

Marshall P

3

1 reference

19 April 2018

Schenck C

4

1 reference

19 April 2018

Lurie N

5

1 reference

19 April 2018

Pheley A

6

1 reference

19 April 2018

Peterson PK

7

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 January 1996

1 reference

19 April 2018

number of pages

8

1 reference

The Journal of Allergy and Clinical Immunology

inferred from page(s)

published in

1 reference

19 April 2018

volume

97

1 reference

19 April 2018

issue

1 Pt 1

1 reference

19 April 2018

page(s)

119-126

1 reference

19 April 2018

Chronic fatigue syndrome: a working case definition.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Allergy and the chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

A Comprehensive Immunological Analysis in Chronic Fatigue Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Chronic fatigue syndrome: clinical condition associated with immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: Preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Chronic Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

H1 receptor antagonist treatment of chronic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

A SELF-RATING DEPRESSION SCALE

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

The chronic mononucleosis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Immediate skin reactivity and its relationship to age, sex, smoking, and occupational exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population: results from the second National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Epstein-Barr Virus Antibodies in Children with Atopic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

Increased serum levels of antibodies to Epstein-Barr virus in adults with history of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2896%2970290-7

7 January 2021

10.1016/S0091-6749(96)70290-7

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018